HCP1803
/ Hanmi
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
February 19, 2025
HM_APOLLO: A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension
(clinicaltrials.gov)
- P3 | N=249 | Completed | Sponsor: Hanmi Pharmaceutical Company Limited | Recruiting ➔ Completed | Trial completion date: Jun 2025 ➔ Dec 2024 | Trial primary completion date: Jun 2025 ➔ Dec 2024
Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Hypertension
May 31, 2024
HM_APOLLO: A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients With Essential Hypertension
(clinicaltrials.gov)
- P3 | N=220 | Recruiting | Sponsor: Hanmi Pharmaceutical Company Limited
New P3 trial • Cardiovascular • Hypertension
September 26, 2023
HM_APOLLO: A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension
(clinicaltrials.gov)
- P3 | N=361 | Completed | Sponsor: Hanmi Pharmaceutical Company Limited | Active, not recruiting ➔ Completed
Trial completion • Cardiovascular • Hypertension
September 22, 2023
A Study to Evaluate the PK, Safety and Tolerability of HCP1803.
(clinicaltrials.gov)
- P1 | N=20 | Completed | Sponsor: Hanmi Pharmaceutical Company Limited | Not yet recruiting ➔ Completed
Trial completion
June 01, 2023
HM_APOLLO: A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension
(clinicaltrials.gov)
- P3 | N=361 | Active, not recruiting | Sponsor: Hanmi Pharmaceutical Company Limited | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Dec 2023 ➔ Jun 2023 | Trial primary completion date: Dec 2023 ➔ Jun 2023
Enrollment closed • Trial completion date • Trial primary completion date • Cardiovascular • Hypertension
February 10, 2023
A Study to Evaluate the PK, Safety and Tolerability of HCP1803.
(clinicaltrials.gov)
- P1 | N=20 | Not yet recruiting | Sponsor: Hanmi Pharmaceutical Company Limited
New P1 trial
July 14, 2022
HM_APOLLO: A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension
(clinicaltrials.gov)
- P2 | N=248 | Completed | Sponsor: Hanmi Pharmaceutical Company Limited | Unknown status ➔ Completed
Trial completion • Cardiovascular • Hypertension
July 14, 2022
HM_APOLLO: A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension
(clinicaltrials.gov)
- P2 | N=245 | Completed | Sponsor: Hanmi Pharmaceutical Company Limited | Recruiting ➔ Completed
Trial completion • Cardiovascular • Hypertension
May 05, 2022
HM_APOLLO: A Phase 3 Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension
(clinicaltrials.gov)
- P3 | N=358 | Not yet recruiting | Sponsor: Hanmi Pharmaceutical Company Limited
New P3 trial • Hypertension
July 13, 2021
HM_APOLLO: A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension
(clinicaltrials.gov)
- P2; N=224; Recruiting; Sponsor: Hanmi Pharmaceutical Company Limited
Clinical • New P2 trial • Hypertension
1 to 10
Of
10
Go to page
1